GWPH News and Press, GW Pharmaceuticals Plc From 01/20/20

Editors' Note: This is the transcript version of the podcast we published Wednesday with Debra Borchardt. We hope you enjoy it. Listen on the go! Subscribe to The Cannabis Investing Podcast on Apple Podcasts , Google Podcasts , Spotify , and Stitcher ....

We could probably all now agree that the biggest naysayers of  GW Pharmaceuticals (NASDAQ: GWPH) and its CBD drug, Epidiolex, have been proved wrong. One GW skeptic said in 2018 that he'd "be shocked if annual Epidiolex sales ever reach $300 million." The drug topped that amount in its f...

To say that the marijuana industry had a bad 2019 wouldn't do justice to just how awful things were . Despite seeming to be on the cusp of profitability, cannabis stocks throughout North America wound up being clobbered by a variety of issues, with a number of the most popular marijuana stocks...

An investment firm has launched its first marijuana exchange-traded fund (ETF) in Europe. The Medical Cannabis & Wellness UCITS ETF (XETRA: CBDX ) began its listing on Tuesday (January 14), and is available to investors on the Deutsche Boerse XETRA exchange based in Germany. The ne...

A bipartisan group of lawmakers introduced a bill in the U.S. House of Representatives on Monday that would give the Food and Drug Administration (FDA) flexibility to allow hemp-derived cannabidiol (CBD) to be sold as a dietary supplement, boosting shares of cannabis stocks such as Charlotte's ...

GW Pharmaceuticals plc (GWPH) 38th Annual J.P. Morgan Healthcare Conference January 14, 2020 14:00 P.M. ET Company Participants Justin Gover - CEO Conference Call Participants Cory Kasimov - J.P. Morgan Presentation Cory Kasimov Hi, good morning everyone. My name is C...

The following slide deck was published by GW Pharmaceuticals plc in conjunction with this Read more ...

GW Pharmaceuticals (NASDAQ: GWPH) released its preliminary fourth-quarter results for 2019 on Sunday. Sales for the quarter totaled $108 million, with $104 million of that coming from the company's popular cannabidiol (CBD)-based drug, Epidiolex. That was well above the $102.4 million that a...

While marijuana has been touted by many for its beneficial medical effects, there are some health conditions where cannabis might not be so good for you. New research from the University of California San Diego School of Medicine showed that tetrahydrocannabinol (THC) -- the cannabis compoun...

While most investors who are looking for marijuana stocks to buy tend to look at the bigger companies in the industry. This often denies the potential of the small to mid-cap players. These smaller companies have much to work with in terms of innovation. Within this young industry, innovation ...